RESUMO
BACKGROUND: To present findings from a retrospective study conducted by the Ultra-Rare Sarcoma Working Group on metastatic low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid (H)-LGFMS/SEF across 28 global centres. METHODS: Patients treated at participating institutions from January 2000 to September 2022 were retrospectively selected. Diagnosis was confirmed by expert pathologists. Primary endpoint was progression-free survival (PFS-1) from metastasis detection to first progression or death. PFS-2 was calculated from therapy initiation. RESULTS: A total of 101 patients were identified (32 LGFMS, 50 SEF, 19 H-LGFMS/SEF). Median (m) follow-up was 62.1 months. mPFS-1 was 28.7, 11.8, and 20.3 months for LGFMS, SEF, and H-LGFMS/SEF, respectively. mOS was 145.8, 41.9, and 113.5 months, respectively. Treatments included anthracycline-based chemotherapy, gemcitabine-based chemotherapy (G), pazopanib, trabectedin, others. mPFS-2 was: 20.1, 5.5, and 3.5 months in H-LGFMS/SEF, SEF, and LGFMS, respectively, with anthracyclines; 19.5, 7.7, and 6.9 months in LGFMS, SEF, and H-LGFMS/SEF, respectively, with pazopanib; 12.0, 9.7, and 3.1 months in H-LGFMS/SEF, LGFMS, and SEF, respectively. Occasional responses occurred with ifosfamide/oral cyclophosphamide, and prolonged stable disease with immune checkpoint inhibitors. CONCLUSIONS: In this series, the largest available, metastatic LGFMS, SEF, and H-LGFMS/SEF showed different courses. Systemic agents have modest efficacy, informing future trials of novel agents for these tumours.
Assuntos
Fibrossarcoma , Humanos , Estudos Retrospectivos , Feminino , Masculino , Fibrossarcoma/tratamento farmacológico , Pessoa de Meia-Idade , Adulto , Idoso , Adulto Jovem , Pirimidinas/uso terapêutico , Indazóis/uso terapêutico , Gencitabina , Trabectedina/uso terapêutico , Adolescente , Sulfonamidas/uso terapêutico , Gradação de Tumores , Antraciclinas/uso terapêutico , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias de Tecidos Moles/tratamento farmacológico , Neoplasias de Tecidos Moles/patologiaRESUMO
Maize Research Institute (MRI) gene bank maintains a collection of 6000 maize accessions. Within this collection over 100 sources of cytoplasmic male sterility (CMS) were found in field trials, i.e. more than 2% of the total accession numbers. These sources are distributed among Yugoslav open-pollinated varieties (4.56% of them contain CMS), as well as introduced heterozygous genotypes and inbred lines. In order to identify cytoplasm types the gene-bank sources of CMS were screened using a PCR assay with specific primers for C, T and S cytoplasms. Predominant cytoplasmic male sterility type among the analyzed accessions was CMS-S. Results were inconclusive for three accessions, i.e. different results for the progenies of two ears per accession were obtained. For another two accessions a new PCR product profile was identified, consisting of one band characteristic for CMS-S and one unspecific for any of the three CMS types. The PCR approach enabled a simple, fast and reliable large scale screening of maize cytoplasm among MRI gene bank accessions, significantly reducing time for cytoplasm characterizations compared to classical method of testing with restorers for each known type of CMS.
Assuntos
Bases de Dados Genéticas , Infertilidade das Plantas/genética , Zea mays/genética , Genótipo , EndogamiaRESUMO
A study was made of the pH value of uterine secretion in 100 women at the age of 18-50 years and with a normal menstrual cycle (28 +/- 2 days). Fifty women had inserted medicated IUDs (Copper T and Multiload Cu 250) and 50 women served as a control group. In the proliferation phase of menstrual cycle 22 women were with the IUDs (of whom 14 had group II and 8 women group III vaginal secretion) and 21 women without any IUD of whom 8 had group II and 13 women group III vaginal secretion. In the secretion phase 28 women were with IUDs, (8 had group II and 20 women group III vaginal secretion) and 29 women from the control group, of whom 17 had group II and 12 women had group III. For the sampling of the intrauterine fluid the aspiration method and for the pH determination the colorimetric method were used. It can be seen that there is no correlation between the group of vaginal secretion and the pH of the uterine fluid, that the presence of a medicated IUD induced an insignificant change in the intrauterine pH, and that the pH value of the uterine fluid ranges from 3.0-9.0 which may be an important factor in the elucidation of certain mechanisms that occur in the uterus in the presence of intrauterine devices.
Assuntos
Dispositivos Intrauterinos Medicados , Útero/metabolismo , Adolescente , Adulto , Feminino , Humanos , Concentração de Íons de Hidrogênio , Dispositivos Intrauterinos de Cobre , Pessoa de Meia-IdadeRESUMO
A study was performed of the pH value of uterine secretion in 250 women at the age of 18-50 years and with a normal menstrual cycle (28 +/- 2 days). Two hundred out of the total number of the women observed had an inserted nonmedicated IUD (Beospir), whereas the remaining 50 women served as the control group. In the study the phase of the menstrual cycle and the group of vaginal secretion were considered. For the sampling of the intrauterine fluid from the uterine cavity the aspiration method was used and for the determination of pH, the colorimetric method. On the basis of the present study it can be seen that there is no correlation between the group of vaginal secretion and the pH of the uterine fluid, that the presence of a nonmedicated IUD induces an insignificant change in the intrauterine pH, and that the pH value of the uterine fluid ranges from 3,0-9,0 which may be an important factor in elucidating certain mechanisms that occur in the uterus in the presence of intrauterine devices.